» Articles » PMID: 29285239

Low Density Lipoprotein - Rosiglitazone - Chitosan-calcium Alginate/nanoparticles Inhibition of Human Tenon's Fibroblasts Activation and Proliferation

Overview
Journal Oncotarget
Specialty Oncology
Date 2017 Dec 30
PMID 29285239
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Anti-fibrotic therapeutic methods with safety and efficiency after glaucoma filtration surgery (GFS) are desirable. In our previous study, by using Human Tenon's Fibroblasts (HTFs) as a model, we proved the expression of peroxisome proliferator activates receptor-γ (PPAR-γ) in HTFs; in addition, rosiglitazone (RSG), an agonist of PPAR-γ, can inhibit transforming growth factorsβ1 (TGF-β1)-induced reactivation of HTFs, thus to inhibit specifically scarring after GFS through intervening TGF-β/Smads signal pathway. However, a better drug delivery way of RSG, to prolong the duration of its function, and to reduce the toxicity of RSG to ocular tissue still remains challenges. Low density lipoprotein receptor (LDLr) is strongly expressed in hyper-proliferation HTFs after GFS. Therefore, we structured targeting LDL-RSG complexes and channel them into HTFs through LDL-LDLr pathway in order to promote anti-proliferation of HTFs and reduce the toxicity to ocular tissue. Meanwhile, in order to improve the release properties of LDL-RSG complexes, we structured slow release system of LDL-RSG/chitosan-calcium alginate - nanoparticles (CSNP), which effectively inhibited TGF-β1-induced HTFs proliferation, synthesis of extracellular matrix and activation of TGF-β1/SMAD pathway. These data suggested that LDL-RSG/CSNP can be a new anti-fibrotic therapeutic method on scarring after GFS and also a novelty administration of RSG.

Citing Articles

Butyrate Ameliorates Graves' Orbitopathy Through Regulating Orbital Fibroblast Phenotypes and Gut Microbiota.

Ouyang P, Qi J, Tong B, Li Y, Cao J, Wang L Invest Ophthalmol Vis Sci. 2025; 66(3):5.

PMID: 40035727 PMC: 11892527. DOI: 10.1167/iovs.66.3.5.


Co-Crystal of Rosiglitazone With Berberine Ameliorates Hyperglycemia and Insulin Resistance Through the PI3K/AKT/TXNIP Pathway and .

He Q, Chen B, Wang G, Zhou D, Zeng H, Li X Front Pharmacol. 2022; 13:842879.

PMID: 35571083 PMC: 9096649. DOI: 10.3389/fphar.2022.842879.


Chitosan and its Derivatives for Ocular Delivery Formulations: Recent Advances and Developments.

Zamboulis A, Nanaki S, Michailidou G, Koumentakou I, Lazaridou M, Ainali N Polymers (Basel). 2020; 12(7).

PMID: 32650536 PMC: 7407599. DOI: 10.3390/polym12071519.


Design and encapsulation of anticancer dual HSP27 and HER2 inhibitor into low density lipoprotein to target ovarian cancer cells.

Alhadad L, Harisa G, Alanazi F Saudi Pharm J. 2020; 28(4):387-396.

PMID: 32273796 PMC: 7132616. DOI: 10.1016/j.jsps.2020.01.020.


Low-density lipoprotein decorated silica nanoparticles co-delivering sorafenib and doxorubicin for effective treatment of hepatocellular carcinoma.

Ye J, Zhang R, Chai W, Du X Drug Deliv. 2019; 25(1):2007-2014.

PMID: 30799656 PMC: 6319454. DOI: 10.1080/10717544.2018.1531953.


References
1.
Zhang Y, Yang X, Bian F, Wu P, Xing S, Xu G . TNF-α promotes early atherosclerosis by increasing transcytosis of LDL across endothelial cells: crosstalk between NF-κB and PPAR-γ. J Mol Cell Cardiol. 2014; 72:85-94. DOI: 10.1016/j.yjmcc.2014.02.012. View

2.
Wang F, Yang S, Yuan J, Gao Q, Huang C . Effective method of chitosan-coated alginate nanoparticles for target drug delivery applications. J Biomater Appl. 2016; 31(1):3-12. DOI: 10.1177/0885328216648478. View

3.
Yu J, Long L, Luo Z, You J . Effect of PPARγ agonist (rosiglitazone) on the secretion of Th2 cytokine in asthma mice. Asian Pac J Trop Med. 2017; 10(1):64-68. DOI: 10.1016/j.apjtm.2016.10.006. View

4.
Skuta G, Parrish 2nd R . Wound healing in glaucoma filtering surgery. Surv Ophthalmol. 1987; 32(3):149-70. DOI: 10.1016/0039-6257(87)90091-9. View

5.
Lama P, Fechtner R . Antifibrotics and wound healing in glaucoma surgery. Surv Ophthalmol. 2003; 48(3):314-46. DOI: 10.1016/s0039-6257(03)00038-9. View